Normandie Université, UNICAEN, Inserm U1086 ANTICIPE «Interdisciplinary Research Unit for Cancer Prevention and Treatment», Biology and Innovative Therapeutics for Ovarian Cancers Group (BioTICLA), Centre de Lutte Contre le Cancer F. Baclesse, Caen, 14076, France
Auto-generated profile, based on publicly available information
Hippolyte Paysant
Normandie Université, UNICAEN, Inserm U1086 ANTICIPE «Interdisciplinary Research Unit for Cancer Prevention and Treatment», Biology and Innovative Therapeutics for Ovarian Cancers Group (BioTICLA), Centre de Lutte Contre le Cancer F. Baclesse, Caen, 14076, France
Novel therapeutic strategies are urgently required for the clinical management of chemoresistant ovarian carcinoma, which is the most lethal of the gynecologic malignancies. miRNAs hold promise because they play a critical role in determining the cell phenotype by regulating several hundreds of targets, which could constitute vulnerabilities of cancer cells. A combination of gain-of-function miRNA screening and real-time continuous cell monitoring allows the identification of miRNAs with robust cytotoxic effects in chemoresistant ovarian cancer cells. Focusing on miR-3622b-5p, we show that it induces apoptosis in several ovarian cancer cell lines by both directly targeting Bcl-xL and EGFR-mediating BIM upregulation. miR-3622b-5p also sensitizes cells to cisplatin by inhibiting Bcl-xL in ovarian cancer cell lines escaping BIM induction. miR-3622b-5p also exerts antimigratory capacities by targeting both LIMK1 and NOTCH1. These wide-ranging antitumor properties of miR-3622b-5p in ovarian cancer cells are mimicked by the associations of pharmacologic inhibitors targeting these proteins. The combination of an EGFR inhibitor together with a BH3-mimetic molecule induced a large decrease in cell viability in a panel of ovarian cancer cell lines and several ovarian patient-derived tumor organoids, suggesting the value of pursuing such a combination therapy in ovarian carcinoma. Altogether, our work highlights the potential of phenotype-based miRNA screening approaches to identify lethal interactions which might lead to new drug combinations and clinically applicable strategies.
1 December 2021 in Drug Design, Development and Therapy
Introduction: With the aim of repositioning commercially available drugs for the inhibition of the anti-apoptotic myeloid cell leukemia protein, Mcl-1, implied in various cancers, five molecules, highlighted from a published theoretical screening, were selected to experimentally validate their affinity toward Mcl-1. Results: A detailed NMR study revealed that only two of the five tested drugs, Torsemide and Deferasirox, interacted with Mcl-1. NMR data analysis allowed the complete characterization of the binding mode of both drugs to Mcl-1, including the estimation of their affinity for Mcl-1. Biological assays evidenced that the biological activity of Torsemide was lower as compared to the Deferasirox, which was able to efficiently and selectively inhibit the anti-apoptotic activity of Mcl-1. Finally, docking and molecular dynamics led to a 3D model for the Deferasirox:Mcl-1 complex and revealed the positioning of the drug in the Mcl-1 P2/P3 pockets as well as almost all synthetic Mcl-1 inhibitors. Interestingly, contrary to known synthetic Mcl-1 inhibitors which interact through Arg263, Deferasirox, establishes a salt bridge with Lys234. Conclusion: Deferasirox could be a potential candidate for drug repositioning as Mcl-1 inhibitor.
Les cellules cancéreuses présentent fréquemment une résistance à l’apoptose impliquée à la fois dans la carcinogénèse et dans la chimiorésistance qui est liée à un déséquilibre entre l’expression des protéines anti- et pro-apoptotiques de la famille Bcl-2. Dans les cancers ovariens, c’est en particulier la surexpression des protéines Bcl-xL et Mcl-1 qui est impliquée dans cette résistance, et notre équipe a démontré l’intérêt de leur inhibition, seule ou de manière concomitante pour tuer les cellules cancéreuses chimiorésistantes. Le travail de thèse présenté ici concerne dans un premier temps l’identification de nouveaux inhibiteurs de Mcl-1. Un travail de pharmacomodulation de la molécule MIM1, après la correction de sa structure, a abouti à l’identification de hits puissants et très sélectifs. La mise en évidence de toxicités cardiaques associées à l’inhibition de Mcl-1 en clinique nécessite la mise en œuvre d’autres approches destinées à cibler davantage la tumeur et éviter ce tissu particulièrement sensible. C’est ainsi que la stratégie PROTAC, qui permet la dégradation d’une protéine cible avec une sélectivité tissulaire importante a vu le jour. La conception de 6 molécules PROTAC dérivées du pyridoclax ou de ses analogues, a permis de mettre en évidence une puissante activité de ces derniers in vitro sur deux lignées tumorales ovariennes. Un important travail de pharmacomodulation (modification du ligand de Mcl-1, de la nature et de la longueur de l’espaceur et de la nature du ligand de l’E3 ligase) est en cours, pour aboutir à la sélection d’une ou plusieurs molécules à évaluer in vivo. Enfin, la dernière partie du manuscrit présente un travail réalisé sur neuf lignées d’organoïdes dérivés de tumeurs ovariennes pour déterminer la sensibilité à 4 inhibiteurs de Mcl-1, et son éventuelle corrélation avec l’expression des protéines de la famille Bcl-2. Ce travail a permis d’identifier des pistes concernant une signature prédictive à valider sur une cohorte plus importante. L’application clinique de ces molécules nécessite de valider leur activité in vivo et de poursuivre le travail d’identification de signatures moléculaires permettant d’identifier les patientes susceptibles de répondre à ces stratégies.
Novel therapeutic strategies are urgently required for the clinical management of chemoresistant ovarian carcinoma, which is the most lethal of the gynecologic malignancies. miRNAs hold promise because they play a critical role in determining the cell phenotype by regulating several hundreds of targets, which could constitute vulnerabilities of cancer cells. A combination of gain-of-function miRNA screening and real-time continuous cell monitoring allows the identification of miRNAs with robust cytotoxic effects in chemoresistant ovarian cancer cells. Focusing on miR-3622b-5p, we show that it induces apoptosis in several ovarian cancer cell lines by both directly targeting Bcl-xL and EGFR-mediating BIM upregulation. miR-3622b-5p also sensitizes cells to cisplatin by inhibiting Bcl-xL in ovarian cancer cell lines escaping BIM induction. miR-3622b-5p also exerts antimigratory capacities by targeting both LIMK1 and NOTCH1. These wide-ranging antitumor properties of miR-3622b-5p in ovarian cancer cells are mimicked by the associations of pharmacologic inhibitors targeting these proteins. The combination of an EGFR inhibitor together with a BH3-mimetic molecule induced a large decrease in cell viability in a panel of ovarian cancer cell lines and several ovarian patient-derived tumor organoids, suggesting the value of pursuing such a combination therapy in ovarian carcinoma. Altogether, our work highlights the potential of phenotype-based miRNA screening approaches to identify lethal interactions which might lead to new drug combinations and clinically applicable strategies.
Supplementary Figure 1 shows that a screening identifies some miRNAs affecting the cell viability of IGROV1-R10 ovarian cancer cell line; Supplementary Figure 2 shows that miR-3622b-5p is poorly expressed in ovarian cancer cells compared to fallopian tubes epithelial cells; Supplementary Figure 3 shows that miR-3622b-5p induces apoptosis in a panel of ovarian cancer cell lines; Supplementary Figure 4 shows that miR-3622b-5p does not sensitize SKOV3 ovarian cancer cell line to platinum; Supplementary Figure 5 shows some targets and associated cell signaling pathways modulated by miR-3622b-5p in several ovarian cancer cell lines; Supplementary Figure 6 shows that miR-3622b-5p sensitizes OAW42-R ovarian chemoresistant cancer cells to cisplatin; Supplementary Figure 7 shows some targets regulated by miR-3622b-5p in SKOV3 cells; Supplementary Table 1 describes the antibodies and the oligonucleotides used in this study.
Epithelial ovarian cancer (EOC) remains a leading cause of gynecologic cancer-related mortality, with frequent relapse and the emergence of resistance to platinum-based chemotherapy and PARP inhibitors (PARPi). Innovative therapeutic strategies are therefore needed, particularly for patients displaying intrinsic or acquired resistance to PARPi. Photodynamic therapy (PDT) could be a good therapeutic alternative. PDT represents a locoregional treatment modality that induces tumor cell death through light-activated reactive oxygen species generation. In this study, we evaluated the activity of a folate receptor alpha (FRα)-targeted photosensitizer (Pyro-PEG-FA) in ovarian cancer models, including patient-derived tumor organoids (PDTOs) exhibiting resistance to olaparib. FRα expression and photosensitizer uptake were confirmed in ovarian cancer cell lines, 3D spheroids, and two independent PARPi-resistant PDTO models. Targeted PDT induced a dose-dependent decrease in viability across all models tested. Importantly, PDT maintained cytotoxic activity in PDTOs resistant to PARPi. In contrast, sequential combination of PARPi and PDT did not demonstrate additive or synergistic effects, as PDT alone was sufficient to induce substantial tumor cell death. These findings indicate that FRα-targeted PDT retains efficacy in PARPi-resistant ovarian cancer organoid models and support its further investigation as a potential therapeutic option in the context of treatment-resistant EOC.